New JAK Inhibitor for Atopic Dermatitis

  • This topic has 0 replies, 1 voice, and was last updated 4 months ago by TDP.
Viewing 0 reply threads
  • Author
    Posts
    • #49017
      TDP
      Keymaster

      On January 14, 2022, the US FDA approved CIBINQO(R) (abrocitinib) oral tablets for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. CIBINQO, which is a Janus kinase (JAK) inhibitor, was approved based on results from 5 clinical trials demonstrating improvement in itching compared with placebo. CIBINQO carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis.

      Prescribing information can be found at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213871s000lbl.pdf

Viewing 0 reply threads

You must be logged in to reply to this topic.

gdpr-image
This website uses cookies to improve your experience. By using this website you agree to our Cookie Policy.
Read more